TY - JOUR
T1 - Pediatric Pleomorphic Xanthoastrocytoma
T2 - A National Database Inquiry on Current Treatment Approaches in the United States
AU - Scarpelli, Daphne B.
AU - Yu, Yun
AU - Tep, Amanda C.
AU - Bergue, Bailey
AU - Degnin, Catherine
AU - Chen, Yiyi
AU - McClelland, Shearwood
AU - Jaboin, Jerry J.
N1 - Publisher Copyright:
© 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.
PY - 2021/12
Y1 - 2021/12
N2 - Background: Pleomorphic xanthoastrocytomas (PXAs) account for <1% of primary brain tumors, occurring predominantly in children and young adults. Surgical resection serves as the primary treatment for PXAs, while radiotherapy (RT) and chemotherapy protocols remain poorly defined. Aim: This study aims to determine current care patterns utilized for pediatric patients (≤ 18 years) diagnosed with PXAs and their effect on overall survival. Methods: The United States National Cancer Database (NCDB) was queried between 2004 and 2015 for pediatric patients (≤18 years) diagnosed with PXAs. Results: From the 224 qualifying patients, most patients proceeded with surgery only (78.1%), while 11.6% of patients received both adjuvant RT and chemotherapy. In the 2010-2015 cohort, patients with subtotal resection were associated with poorer prognosis than those with gross-total resection (hazard ratio = 17.44, 95% confidence interval = 2.10-144.90, p <.001). RT and chemotherapy recipients were similarly associated with poorer survival than those treated with surgery only, with p-values of <.001 and respective hazard ratios of 3.82 (95% confidence interval = 1.85-7.90) and 6.68 (95% confidence interval = 3.21-13.89). The key factors impacting the probability of RT delivery involved WHO grade (p <.001) and chemotherapy administration (p <.001). However, WHO grade alone did not significantly impact survival (p-value =.088). Conclusion: Maximally safe resection is the current treatment goal for patients with PXAs. RT and chemotherapy are poorly utilized but had a greater role in managing more aggressive cases of PXAs. Additional research focusing on the impact of adjuvant therapies on tumor progression is needed to better guide treatment decisions.
AB - Background: Pleomorphic xanthoastrocytomas (PXAs) account for <1% of primary brain tumors, occurring predominantly in children and young adults. Surgical resection serves as the primary treatment for PXAs, while radiotherapy (RT) and chemotherapy protocols remain poorly defined. Aim: This study aims to determine current care patterns utilized for pediatric patients (≤ 18 years) diagnosed with PXAs and their effect on overall survival. Methods: The United States National Cancer Database (NCDB) was queried between 2004 and 2015 for pediatric patients (≤18 years) diagnosed with PXAs. Results: From the 224 qualifying patients, most patients proceeded with surgery only (78.1%), while 11.6% of patients received both adjuvant RT and chemotherapy. In the 2010-2015 cohort, patients with subtotal resection were associated with poorer prognosis than those with gross-total resection (hazard ratio = 17.44, 95% confidence interval = 2.10-144.90, p <.001). RT and chemotherapy recipients were similarly associated with poorer survival than those treated with surgery only, with p-values of <.001 and respective hazard ratios of 3.82 (95% confidence interval = 1.85-7.90) and 6.68 (95% confidence interval = 3.21-13.89). The key factors impacting the probability of RT delivery involved WHO grade (p <.001) and chemotherapy administration (p <.001). However, WHO grade alone did not significantly impact survival (p-value =.088). Conclusion: Maximally safe resection is the current treatment goal for patients with PXAs. RT and chemotherapy are poorly utilized but had a greater role in managing more aggressive cases of PXAs. Additional research focusing on the impact of adjuvant therapies on tumor progression is needed to better guide treatment decisions.
UR - http://www.scopus.com/inward/record.url?scp=85105352422&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105352422&partnerID=8YFLogxK
U2 - 10.1002/cnr2.1415
DO - 10.1002/cnr2.1415
M3 - Article
C2 - 33963808
AN - SCOPUS:85105352422
SN - 2573-8348
VL - 4
JO - Cancer Reports
JF - Cancer Reports
IS - 6
M1 - e1415
ER -